Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Biocept Enters Clinical Collaboration With UC, San Diego Moores Cancer Center

By Drug Discovery Trends Editor | March 25, 2015

Biocept, Inc., a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), announced that it has entered into a clinical collaboration with University of California, San Diego Moores Cancer Center to determine the clinical utility of detecting biomarkers present in CTCs and ctDNA in blood samples for non-small cell lung cancer patients using Biocept’s OncoCEE LU platform and CEE-Selector technology.
 
Biocept offers a highly sensitive and quantitative blood-based method for the detection and monitoring of cancer mutations, which can help inform treatment decisions based on genomic information. The Company is engaged in clinical study collaborations designed to demonstrate the utility of its liquid biopsy diagnostics to detect biomarker status in cancer patients, and for the assessment of tumor treatment response over time.
 
“Genetic alterations and mutations are observed in non-small cell lung cancer, the most prevalent of all lung cancers. We are interested in determining and monitoring the molecular status in patients with lung cancer who are progressing despite treatment with first-line therapy,” said Hatim Husain, MD, an assistant professor of hematology-oncology at University of California, San Diego Moores Cancer Center. “A serious clinical challenge in treating this disease is to obtain lung tissue biopsies. Severe complications from these biopsy procedures can occur and are associated with significant cost. A blood-based liquid biopsy could reduce the need to conduct lung tissue biopsies, and also offers the ability to obtain critical genomic information for improved patient management on a more frequent basis.”
 
“Thanks to rapid advances in precision medicine, clinicians and researchers understanding of lung cancer biology and the underlying genetic alterations that drive it, is growing,” said Michael Nall, CEO of Biocept. “Select targeted drug therapies are currently available and many other therapies are in clinical trials. These therapies are designed to treat cancer patients with specific genetic alterations. Our blood tests enable physicians to detect and monitor genetic changes of a patient’s tumor over time in order to most effectively treat the cancer, forgoing the need for an invasive surgical biopsy. As cancer becomes a chronic disease, we believe that the clinical information provided by our blood test ordered either at the time of diagnosis or during treatment for monitoring will improve the efficacy of targeted cancer treatment and help provide solutions for the issue of acquired resistance.”
 
“By monitoring the levels of the resistance markers using Biocept’s highly sensitive blood test, the recurrence of disease in patients being treated with targeted therapies becomes more predictable,” said Lyle Arnold, Senior Vice President and Chief Scientific Officer for Biocept. “Having accurate, sensitive and quantifiable current genomic information related to a patient’s tumor is a major advance and we believe it will become the standard of care.”
 
Source: Biocept

Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE